United Therapeutics (UTHR) Misses Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
United Therapeutics Corp. (UTHR) PT Lowered to $223 at Jefferies
February 25, 2022 8:44 AM ESTJefferies analyst Eun Yang lowered the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $223.00 (from $235.00) while maintaining a Buy rating.
The analyst commented, "Though disappointing, there are rational explanations for 4Q21 key products sales miss & another FDA approval delay for... More



